Next |
home / stock / imtx / imtx message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $IMTX 27% v4,9M c9.33 f76,67M h9.98 ML5.9 | znewcar1 | investorshangout | 05/02/2023 8:37:44 PM |
$IMTX: IMA203 update | FACT-MASTER | investorshub | 05/02/2023 1:09:54 PM |
$IMTX MomentumIts gaining | Solarfuture | investorshub | 05/01/2023 9:52:32 PM |
$IMTX Price trading last up | FACT-MASTER | investorshub | 05/01/2023 3:14:08 PM |
must see | FACT-MASTER | investorshub | 05/01/2023 12:56:02 PM |
what do you make of this data? | FACT-MASTER | investorshub | 04/30/2023 5:41:24 PM |
MomentumIts gaining | FACT-MASTER | investorshub | 04/30/2023 2:51:55 AM |
bulls and bears | FACT-MASTER | investorshub | 04/28/2023 9:02:37 PM |
Price gaining | Solarfuture | investorshub | 04/27/2023 6:54:53 PM |
Price gaining | jondoeuk | investorshub | 04/27/2023 10:11:15 AM |
should we be shorting? | FACT-MASTER | investorshub | 04/26/2023 11:59:28 AM |
and the shorts continue | FACT-MASTER | investorshub | 04/23/2023 7:04:54 AM |
$IMTX news out | FACT-MASTER | investorshub | 04/22/2023 12:22:43 AM |
$IMTX The trading | jondoeuk | investorshub | 04/21/2023 4:25:59 AM |
$IMTX What do you make of this? | Solarfuture | investorshub | 04/18/2023 4:17:51 AM |
$IMTX Price gaining last up | FACT-MASTER | investorshub | 04/14/2023 3:41:18 PM |
$IMTX The gaining | Solarfuture | investorshub | 04/11/2023 3:10:43 PM |
short squeeze all day | Solarfuture | investorshub | 04/05/2023 3:22:22 PM |
$IMTX MomentumIts now up | FACT-MASTER | investorshub | 04/04/2023 9:19:15 PM |
must see | Solarfuture | investorshub | 04/03/2023 5:03:07 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective r...
2024-04-02 14:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...